Table 1.
Characteristics of registry cohort
| Characteristic | Never infected | SARS-CoV-2 positive | Overall |
|---|---|---|---|
| Number in cohort | 156 017 | 30 088 | 186 105 |
| Age, median [IQR], years | 46 [32, 62] | 43 [30, 57] | 46 [32, 62] |
| Sex (%) | |||
| Female | 89 547 (57.4) | 16 718 (55.6) | 106 265 (57.1) |
| Male | 66 470 (42.6) | 13 370 (44.4) | 79 840 (42.9) |
| Race (%) | |||
| Black | 17 106 (11.0) | 3274 (10.9) | 20 380 (11.0) |
| Other race or multiracial | 7901 (5.1) | 1714 (5.7) | 9615 (5.2) |
| Unknown/not reported | 18 996 (12.2) | 5924 (19.7) | 24 920 (13.4) |
| White | 112 014 (71.8) | 19 176 (63.7) | 131 190 (70.5) |
| Ethnicity (%) | |||
| Hispanic/Latino | 4759 (3.1) | 1217 (4.0) | 5976 (3.2) |
| Non-Hispanic/Non-Latino | 128 049 (82.1) | 21 936 (72.9) | 149 985 (80.6) |
| Unknown/not reported | 23 209 (14.9) | 6935 (23.0) | 30 144 (16.2) |
| Received care at VUMC prior to SARS-CoV-2 test (%)a | 106 839 (68.5) | 20 860 (69.3) | 127 699 (68.6) |
| SARS-CoV-2 testing indication (%) | |||
| Asymptomatic screeningb | 89 727 (57.5) | 6095 (20.3) | 95 822 (51.5) |
| Symptomatic testing | 66 290 (42.5) | 23 993 (79.7) | 90 283 (48.5) |
| EHR observation time | |||
| After SARS-CoV-2 test, median [IQR], days | 420 [267, 533] | 392 [317, 459] | 412 [274, 528] |
| After recovery, median [IQR], days | 378 [215, 495] | 361 [285, 427] | 374 [224, 489] |
| Hospitalization associated with SARS-CoV-2 test (%)c | 43 146 (27.7) | 3393 (11.3) | 46 539 (25.0) |
| Severe COVID-19 (%)d | – | 2358 (7.8) | – |
| Follow-up visit type (%)e | |||
| Any follow-up visit | 96 615 (61.9) | 16 583 (55.1) | 113 198 (60.8) |
| Office visit | 89 559 (57.4) | 15 593 (51.8) | 105 152 (56.5) |
| Laboratory/anticoagulation visit | 42 646 (27.3) | 7216 (24.0) | 49 862 (26.8) |
| Inpatient surgery or procedure | 27 213 (17.4) | 4091 (13.6) | 31 304 (16.8) |
| Telemedicine visit | 16 617 (10.7) | 2478 (8.2) | 19 095 (10.3) |
| Outpatient surgery or procedure | 19 725 (12.6) | 2728 (9.1) | 22 453 (12.1) |
| Allied health practitioner visitf | 14 821 (9.5) | 2580 (8.6) | 17 401 (9.4) |
| Infusion/radiation care | 4043 (2.6) | 542 (1.8) | 4585 (2.5) |
| Maternity care | 3899 (2.5) | 482 (1.6) | 4381 (2.4) |
| Outpatient observation in Emergency Department | 2403 (1.5) | 422 (1.4) | 2825 (1.5) |
| Inpatient medical admission | 1197 (0.8) | 1239 (4.1) | 2436 (1.3) |
| Time from SARS-CoV-2 test to first follow-up visit, median [IQR], days | 66 [44, 139] | 86 [48, 181] | 69 [44, 145] |
| Pregnant during study observation period (%) | 7565 (4.8) | 609 (2.0) | 8174 (4.4) |
| Pregnant around time of SARS-CoV-2 test (%) | 4488 (2.9) | 189 (0.6) | 4677 (2.5) |
| Died during postacute phase (%) | 1535 (1.0) | 158 (0.5) | 1693 (0.9) |
Defined as having at least 2 visits at VUMC prior to SARS-CoV-2 test separated by at least 180 days.
Reasons for asymptomatic screening included: asymptomatic admission to the hospital for another diagnosis, preprocedural or presurgical screening, known SARS-CoV-2 exposure, prereceipt of immunosupressive or antineoplastic therapy, pretransplant evaluation, or requirement for placement in postacute care or long-term nursing care.
SARS-CoV-2 test performed within 15 days prior to a hospital admission or during a hospital admission.
Severe COVID-19: admitted to hospital and received supplemental oxygen.
Some patients had more than 1 visit type.
Allied health practitioner visits included visits coded as being nurse-only visits, dietitian or nutritionist visits, and clinical support or educational visits.